Plan safe, shared and reversible medicine reduction when harms or burden outweigh benefit, while preventing withdrawal, disease recurrence and accidental loss of treatments that remain important to the person.
Begin with the decision the person faces, not a list of medicines to remove. Ask which outcomes matter, what burden is unacceptable and how much uncertainty they will tolerate. Determine capacity for each material decision and provide accessible information, interpreter support or an advocate. If capacity is absent, make and document a least-restrictive best-interests decision that considers previous wishes and those close to the person.
Build an indication-and-outcome table. For each medicine record why it started, who owns it, intended duration, evidence of benefit, current response, time to benefit, adverse effects, monitoring and what would happen if it stopped. Check whether the indication resolved, whether duplicate mechanisms exist and whether another drug is treating its adverse effect.
Prioritise rather than attempting wholesale change. Immediate toxicity and dangerous interaction come first. Next address no indication, duplication, monitoring failure, high anticholinergic or sedative burden and treatments opposing the person's goals. Preserve essential replacement, disease-control and symptom-relief treatment. In limited prognosis, consider whether benefit is likely within the relevant time while avoiding assumptions that comfort always means fewer drugs.
Frailty, organ impairment, adverse effects, limited prognosis or altered goals can make previous long-term prescribing no longer proportionate.
A time-limited condition ends, duplicate therapy persists, or the original indication and evidence of benefit cannot be established.
Complex timing, swallowing, monitoring, cost, dependence on carers and unwanted effects can outweigh an otherwise modest benefit.
Recognising that one medicine caused a symptom allows removal of both the culprit and an unnecessary downstream treatment.
Receptor and endocrine adaptation during chronic exposure makes sudden removal produce withdrawal, rebound or acute hormonal deficiency.
Symptoms may recur because the treated condition remains active, which differs from a transient discontinuation syndrome.
Reducing exposure can improve sedation, posture, cognition and renal risk, but recovery speed depends on half-life and tissue effects.
Changing one priority medicine at a time creates interpretable evidence about benefit, withdrawal and recurrence for future decisions.
The indication has ended, benefit is absent or duplicate exposure creates avoidable harm.
Long duration, high dose, short half-life, previous withdrawal or physiological dependence requires an individual taper.
Novel sensory, autonomic, sleep or gastrointestinal symptoms follow closely after a dose reduction.
The original syndrome returns in its recognisable form and persists despite taper adjustment.
Hypotension, hypoglycaemia, seizure, hallucinations or autonomic instability after abrupt withdrawal is time critical.
A transition, formulation problem or supply gap stops essential treatment without a clinical decision.
Symptoms begin in a drug- and half-life-related pattern after reduction and may include sensory, autonomic, sleep or psychological features.
The original disease returns with its characteristic phenotype and trajectory rather than a novel cluster of withdrawal symptoms.
Infection, pain, metabolic disturbance and bereavement can coincide with tapering and should not be misattributed automatically.
Fear and prior experience can amplify symptoms, but this possibility must never be used to dismiss genuine withdrawal or relapse.
Abrupt sedative, steroid, opioid or psychotropic cessation can cause seizures, adrenal failure, delirium or profound distress.
Removing effective cardiovascular, neurological or psychiatric treatment without monitoring can cause preventable admission and functional decline.
Unilateral stopping or minimising symptoms can make people conceal use, refuse future review or obtain medicines elsewhere.
Stopping only the downstream treatment leaves the causal medicine and symptom active, creating repeated diagnostic and prescribing work.
A deliberate trial stop becomes permanent accidentally, or a discontinued medicine is restarted from an outdated list without context.
Timing, novel symptoms and rapid response to reinstatement may distinguish discontinuation from returning disease.
A fixed milligram reduction can represent an increasingly large proportional change near the end.
Shared permission to pause or restart often makes a careful deprescribing attempt more acceptable.
Preserving essential replacement or adding effective symptom care may enable removal of a harmful substitute.
A clear stop reason and outcome stops an outdated list from silently reinstating an unsuccessful medicine.
Presenting deprescribing as a numerical target or cost-saving exercise.
Stopping long-term corticosteroid, benzodiazepine or antiseizure therapy abruptly.
Assuming every symptom during tapering is relapse of the original condition.
Changing several psychoactive medicines simultaneously without baseline measures.
Ignoring swallowing, formulation and supply barriers during a complex taper.
Continuing reduction despite intolerable withdrawal without shared reassessment.
Failing to remove stopped strengths from repeat and care-home administration records.
Your practice draft is saved in this browser.
A 79-year-old has taken a benzodiazepine nightly for eight years and wishes to stop. There is no acute toxicity. Which approach is most appropriate?
National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes
Classify withdrawal risk. Corticosteroids can suppress the hypothalamic-pituitary-adrenal axis; benzodiazepines and alcohol can produce seizures and delirium; opioids cause autonomic and gastrointestinal withdrawal; antidepressants can cause dizziness, electric-shock sensations, anxiety and sleep disturbance; beta-blocker cessation can provoke adrenergic rebound. Antiseizure and antipsychotic decisions often require specialist coordination.
For medicines associated with dependence or withdrawal, agree a slow, proportionate, stepwise plan. NICE advises that reductions may need to become smaller at lower doses and that the schedule should be acceptable, modifiable and supported. Do not promise a fixed completion date. If intolerable symptoms occur, pause, make a smaller reduction or return to the previous tolerated dose before reviewing the next step.
Distinguish discontinuation from relapse using timing and phenotype. Withdrawal often starts soon after reduction, can include symptoms unlike the original illness and may improve rapidly after reinstatement. Relapse resembles the original disorder and may evolve more slowly, although overlap is common. Record baseline symptoms before change and use the same measure during follow-up.
Optimise the surrounding plan. Replace a sedative's function with sleep, pain or anxiety treatment; correct inhaler technique before stopping respiratory therapy; provide bowel care when opioids remain; and simplify timing or formulation. A successful reduction is less likely if the original distress, access barrier or carer workload is ignored.
Consider organ and functional modifiers. Renal or hepatic decline can justify faster safety action but also increases withdrawal and disease risk if several medicines change. Frailty and falls make sedation and hypotension priorities. Swallowing difficulty may require formulation review rather than discontinuing essential therapy. Nutrition and low body weight alter exposure and resilience.
Create a written action plan: current and target dose, formulation, interval, expected symptoms, red flags, who to contact and next review. Ensure enough of the correct strength is supplied and remove obsolete strengths to prevent error. Pharmacy can support dose forms and adherence; specialist teams should lead where indication or taper complexity exceeds generalist expertise.
At each review ask about the intended gain—alertness, posture, bowel function, pain, sleep, mood or treatment burden—and harm from the change. Decide together to continue, pause, reverse or end the trial. When stopping is complete, update repeats, care records, pharmacy and specialist correspondence and state whether the medicine should remain avoided or can be reconsidered.